Latest News

NEWPORT BEACH, Calif. — jCyte, Inc., a pioneering biotechnology company dedicated to preserving and restoring vision in patients with retinitis pigmentosa (RP) and other degenerative retinal disorders, is pleased to announce the successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration (FDA) held...
TORONTO, Canada – JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes (T1D), a chronic autoimmune condition, and the role screening could play in the early detection of this disease. Nationally, the number of individuals diagnosed with T1D is growing at an estimated...
SHANGHAI, China — Jemincare, a leading pharmaceutical company from China, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration...
SHANGHAI, China — In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion. The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target...
Changchun, China – Scientists have identified a new organelle in liver cells called the mitochondria-lysosome-related organelle (MLRO). This discovery could improve our understanding of chronic liver diseases like alcohol-associated liver disease (ALD) and metabolic dysfunction-associated fatty liver disease (MAFLD). Mitochondria are essential components of cells, often called the “powerhouses” because...
Changchun, China – While heavy drinking is a well-established risk factor for liver cancer, the specific mechanisms by which alcohol contributes to A-HCC remain unclear. This insightful review, published in Hepatology, provides a comprehensive summary of the pathogenesis, heterogeneity, preclinical approaches, epigenetic and genetic profiles of A-HCC. Compared to other types of...
BOSTON, Mass. — Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19,...